Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26347053 | 0.87 | PPM1B (0.43) | PPM1BPTPN1PPP1CCALDH1A1NPSR1 | |
| SCHEMBL13897031 | 0.84 | SMN1; SMN2 (0.34) | PPM1BPTPN1PPP1CCTSHR | |
| SCHEMBL11367332 | 0.82 | PPM1B (0.38) | PPM1BPTPN1PPP1CCALDH1A1NPSR1 | |
| SCHEMBL12415457 | 0.79 | CYP3A4 (0.36) | ALDH1A1TSHR | |
| SCHEMBL14586744 | 0.79 | THRA (0.32) | PPM1BPTPN1PPP1CC | |
| SCHEMBL20313807 | 0.77 | KMT2A (0.31) | ALDH1A1NPSR1 | |
| SCHEMBL12415445 | 0.77 | PPM1B (0.35) | PPM1BPTPN1PPP1CCALDH1A1NPSR1 | |
| SCHEMBL12415463 | 0.76 | CYP19A1 (0.36) | ALDH1A1NPSR1TSHRKDM4E | |
| SCHEMBL18432732 | 0.75 | PPM1B (0.37) | PPM1BPTPN1PPP1CC | |
| SCHEMBL12415460 | 0.75 | PPM1B (0.37) | PPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080984-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | ZANNA SCITECH CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| US-20110172381-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | ZANNA SCITECH CO., LTD. (CN) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172381-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | RCSD1, RRP12, TIAM1 | PPM1B 2985/4885PTPN1 3461/4885PPP1CC 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.